Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes

ERBB2 amplification is a prognostic marker for aggressive tumors and a predictive marker for prolonged survival following treatment with HER2 inhibitors. We attempt to sub-group HER2+ tumors based on amplicon structures and co-amplified genes. We examined five HER2+ cell lines, three HER2+ xenograph...

Descripción completa

Detalles Bibliográficos
Autores principales: Maoz, Myriam, Devir, Michal, Inbar, Michal, Inbar-Daniel, Ziva, Sherill-Rofe, Dana, Bloch, Idit, Meir, Karen, Edelman, David, Azzam, Salah, Nechushtan, Hovav, Maimon, Ofra, Uziely, Beatrice, Kadouri, Luna, Sonnenblick, Amir, Eden, Amir, Peretz, Tamar, Zick, Aviad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906288/
https://www.ncbi.nlm.nih.gov/pubmed/31827209
http://dx.doi.org/10.1038/s41598-019-55455-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906288/
https://www.ncbi.nlm.nih.gov/pubmed/31827209
http://dx.doi.org/10.1038/s41598-019-55455-6

Ejemplares similares